Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...
Yantai, March 8, 2024 – Boan Biotech (6955.HK) today announced the completion of a Phase 3 clinical trial (a comparative study of efficacy, safety, and immunogenicity) for its Dulaglutide Inject...